Adagio publishes preclinical data on lead coronaviruses antibody
Data demonstrate ADG2 binds to all known variants of SARS-CoV-2 and is not impacted by known circulating resistance mutations
2021-01-25
(Press-News.org) -Data demonstrate ADG2 binds to all known variants of SARS-CoV-2 and is not impacted by known circulating resistance mutations-
-Company expects to begin clinical studies for a half-life extended version of ADG2 for the treatment and prevention of COVID-19 in early 2021-
Waltham, MA - January 25, 2021- Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all known SARS-CoV-2 variants. Uniquely, ADG2 also showed broad and potent neutralization against a range of sarbecoviruses that pose a threat to humans and protective efficacy in murine models of SARS and COVID-19. The data show that ADG2 effectively binds to and has the potential to protect against common circulating SARS-CoV-2 variants as well as future SARS-related viruses with pandemic potential. Adagio's half-life engineered version of ADG2, called ADG20, could offer protection against COVID-19 for up to a year. Adagio expects ADG20 to enter Phase 1 clinical studies in early 2021.
"These studies demonstrate our lead antibody shows comparable or higher neutralization potency against SARS-CoV-2 than leading antibodies currently in development for COVID-19 and binds effectively to all of the most commonly circulating SARS-CoV-2 variants, indicating that it should not be affected by known resistance mutations. Unlike most antibodies currently in clinical development or approved for emergency use, ADG20 binds to a highly conserved epitope, so we believe it will also be effective against future emerging SARS-CoV-2 strains and related pre-emergent sarbecoviruses," said Laura Walker, Ph.D., chief scientific officer of Adagio.
Data highlights:
Potency and breadth of coverage
ADG2 (the precursor to ADG20) provided complete protection against severe SARS-CoV-2 and SARS-CoV disease in murine models of COVID-19 and SARS, respectively.
When compared to other mAbs in development or approved for emergency use, ADG2 showed similar or higher potency against SARS-CoV-2 in two authentic neutralization assays.
ADG20 demonstrated strong binding to all commonly circulating SARS-CoV-2 variants.
ADG2 also showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014).
The epitope targeted by ADG2 is highly conserved across clade 1 sarbecoviruses, and ADG2 binds with high affinity to a large panel of clade I sarbecovirus receptor binding domains (RBDs).
Viral resistance variants
ADG2 binds with high affinity to more than 30 of the most frequently observed SARS-CoV-2 RBD variants reported in the GISAID database, including the known variants resistant to other monoclonal antibodies in development or approved for emergency use.
Notably, no mutations have been reported at key ADG20 contact residues in full length viral genomic sequences (>152,000) of SARS-CoV-2 included in the GISAID database as of December 9, 2020, suggesting a low risk of pre-existing resistance to ADG20 in the clinic.
Other enhanced attributes
In vitro engineering of ADG2 avoided many of the common pitfalls associated with monoclonal antibody enhancements. Specifically, ADG2 demonstrated favorable biophysical properties in a series of in vitro assays that have been shown to be predictive of downstream behaviors such as serum half-life, ease of manufacturing, ability to formulate to high concentrations, and long-term stability.
Although not included in the pre-publication, Adagio also engineered ADG2 to extend serum half-life and enhance mucosal localization.
"As we look to the future, it is clear we will need potent treatment and prevention for not only COVID-19 but also for future coronaviruses, which we can now say with near certainty will continue to emerge," said Tillman Gerngross, Ph.D., chief executive officer of Adagio. "Based on these data, we believe ADG20 has the potential to offer unsurpassed treatment and prevention for COVID-19 while serving as a potent and broadly protective countermeasure to protect against resistant strains of SARS-CoV-2 as well as future sarbecovirus threats. Importantly, we took our time to develop ADG20 without sacrificing duration of effect, manufacturability, and affordability. We look forward to advancing ADG20 into the clinic in early 2021 to learn how it may provide protection from the greatest pandemic of our lifetime."
INFORMATION:
About Adagio Therapeutics
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used in both treatment and durable prevention. Our candidates are engineered using industry-leading antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program, ADG20, is expected to enter the clinic in early 2021. ADG20 was designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability. For more information: http://www.adagiotx.com
Media Contact:
Lindsay G. Deefholts
416-301-7966
ldeefholts@scientpr.com
Investor Contact:
Jane Henderson
jhenderson@adagiotx.com
ELSE PRESS RELEASES FROM THIS DATE:
2021-01-25
Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. The results suggest plitidepsin should be further evaluated as a COVID-19 therapy, the authors say; because it targets a host protein rather than a viral protein, if treatment proves successful in humans, the SARS-CoV-2 virus won't be easily able to gain resistance ...
2021-01-25
A new approach to mapping viral mutations that "escape" leading clinical antibodies has revealed mutations in the SARS-CoV-2 virus that allow it to evade treatments, including a single amino-acid mutation that fully escapes Regeneron's antibody cocktail. These maps, say the authors, demonstrate that prior characterization of escape mutations was incomplete. They will also help to enable immediate interpretation of the effects of the mutations cataloged by viral genomic surveillance, say the authors. Several antibodies are in use or under development as therapies to treat COVID-19. As new SARS-CoV-2 variants emerge, it ...
2021-01-25
Researchers have engineered an antibody that neutralizes SARS-CoV-2 with a potency that "rivals" current lead SARS-CoV-2 clinical neutralizing antibodies, and that also broadly neutralizes a range of clade 1 sarbecoviruses. Their antibody, ADG-2, studied in mice, represents a "promising candidate" for the prevention and treatment of not only COVID-19, they say, but also of future respiratory diseases caused by SARS-related coronaviruses. Although two vaccines and two monoclonal antibody (mAb) therapies have been authorized for emergency use by the FDA, it is unknown whether these vaccines and treatments will provide broad protection against new emerging SARS-CoV-2 strains that originate in humans or animal reservoirs; this is partly ...
2021-01-25
During the first wave of the COVID-19 pandemic, nearly one in four families responded that they would be unlikely to bring their child to the Emergency Department if they had an emergency condition, according to a survey from Ann & Robert H. Lurie Children's Hospital of Chicago published in the journal Academic Emergency Medicine. Greater hesitancy to seek emergency care was found in families living in under-resourced communities, those who rely on public insurance and in families who are Black, Latinx or Asian.
"We observed greater hesitancy to use the Emergency Department among more vulnerable demographic groups who historically showed high utilization of emergency care for their children," ...
2021-01-25
Cancer is the second leading cause of death in the world. The number of deaths and incidences is increasing each year. The metal-based anticancer drugs were used clinically worldwide, but suffer from poor selectivity, serious side effects and drug resistance. Tumor-targeting drug development is the basis for precise cancer treatment.
Recently, Professor Hongke Liu of Nanjing Normal University, Professor Jing Zhao and Academician Zijian Guo of Nanjing University have made breakthrough achievements in anticancer drug development. They proposed a "bio-orthogonally catalyzed lethality" (BCL) strategy ...
2021-01-25
Hernias are one of the most common soft tissue injuries. Hernias form when intra-abdominal content, such as a loop of the intestine, squeezes through weak, defective or injured areas of the abdominal wall.
The condition may develop serious complications, therefore hernia repair may be recommended. Repair consists of surgically implanting a prosthetic mesh to support and reinforce the damaged abdominal wall and facilitate the healing process. However, currently used mesh implants are associated with potentially adverse postsurgical complications.
"Although hernia mesh implants are mechanically strong and support abdominal tissue, making the patient feel comfortable initially, ...
2021-01-25
Musical notes that sound pleasant together can form a harmony. These notes are usually in a special relationship with each other: when expressed as frequencies, their ratios result in simple fractions, such as four-thirds or three-halves. Similarly, a planetary system can also form a kind of harmony when planets, whose orbital period ratios form simple fractions, regularly attract each other with their gravity. When one planet takes three days to orbit its star and its neighbor takes two days, for example. Using the CHEOPS space telescope, scientists, led by astrophysicist Adrien Leleu of the Center for Space and Habitability of the University of Bern, the University of Geneva and ...
2021-01-25
HOUSTON - (Jan. 25, 2021) - A new theory that could explain how unconventional superconductivity arises in a diverse set of compounds might never have happened if physicists Qimiao Si and Emilian Nica had chosen a different name for their 2017 model of orbital-selective superconductivity.
In a study published this month in npj Quantum Materials, Si of Rice University and Nica of Arizona State University argue that unconventional superconductivity in some iron-based and heavy-fermion materials arises from a general phenomenon called "multiorbital singlet pairing."
In superconductors, electrons form pairs and flow without resistance. Physicists cannot fully explain how ...
2021-01-25
Coastal Blue Carbon (BC), which includes mangrove and saltmarsh tidal wetlands, of which was first coined a decade ago to describe the disproportionately large contribution of coastal vegetated ecosystems to global carbon sequestration. The role of BC in climate change mitigation and adaptation has now reached international prominence. Recent studies have reported BC's unique role in mitigating climate change, projected coastal wetlands area change, carbon stocks in response to historical sea level rise fluctuations, and the future roadmap relative to carbon sequestration studies. However, several questions remain unanswered:
Q1. What is the global extent and spatial distribution ...
2021-01-25
Solar-driven photoelectrochemical (PEC) water splitting is an attractive approach to convert solar energy into chemical energy. Among many photoelectrode materials, crystalline silicon (c-Si) has drawn considerable attention because of its earth abundance, narrow bandgap, and suitable band edge position for hydrogen evolution reaction (HER). However, c-Si suffers from low photovoltage generated from the solid-liquid junction.
Various strategies, such as the construction of p-n homojunctions, metal-insulator-semiconductor (MIS) junctions and p-n heterojunctions, have been adopted to obtain high photovoltage. The MIS junctions have been the focus of attention in PEC water splitting due to their simple fabrication and the potential to achieve higher efficiencies than p-n ...
LAST 30 PRESS RELEASES:
[Press-News.org] Adagio publishes preclinical data on lead coronaviruses antibody
Data demonstrate ADG2 binds to all known variants of SARS-CoV-2 and is not impacted by known circulating resistance mutations
